Biofrontera Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; this is an annual filing, not a standalone fourth-quarter report. Unless otherwise stated, amounts are in U.S. dollars. The filing compares FY 2022 with FY 2021.
Business context
Biofrontera is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology. Its principal product is licensed Ameluz, used with BF-RhodoLED lamps for photodynamic treatment of actinic keratoses. It also sells licensed Xepi for impetigo. Product sales are its sole source of product revenue, and Ameluz is the primary revenue driver. The company relies on licensors and contract manufacturers for product supply, development and regulatory activities.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Net revenue | $28.7 million | $24.1 million |
| Operating loss | $18.6 million | $25.2 million |
| Net loss | $0.6 million | $37.7 million |
| Adjusted EBITDA (non-GAAP) | $(18.1) million | $(12.6) million |
| Operating cash flow | $(16.2) million | $(26.7) million |
| Cash and cash equivalents at year-end | $17.2 million | $24.5 million |
- Net revenue increased 19.0%; product revenue rose 18.7% to $28.5 million. Ameluz revenue grew by $4.3 million, principally from higher order volume ($3.7 million) and higher prices ($0.6 million).
- Using reported revenue less cost of revenues, gross profit was approximately $13.5 million, or about 47% of revenue. The filing does not present this as a separately reported margin.
- The FY 2022 net loss was far lower than in 2021, but results included a $16.4 million non-cash gain from changes in warrant fair value and a $1.7 million non-cash gain on equity investments. Operating loss remained $18.6 million. Adjusted EBITDA loss widened, and its margin fell to (63.0%) from (52.3%) as operating costs outpaced revenue growth.
- Current assets were $43.1 million and current liabilities $20.9 million at year-end. Current assets included $10.5 million of Biofrontera AG equity securities, which the company said it intended to liquidate within 12 months. Total liabilities were $27.0 million; stockholders’ equity was $23.9 million.
- Operating cash use improved year over year, but cash declined by $7.3 million. Financing provided $14.0 million, including $9.4 million net proceeds from a private placement and $4.6 million from warrant exercises. Investing used $5.2 million, mainly to purchase Biofrontera AG shares.
- The company reported $7.3 million of Maruho start-up-cost financing in current acquisition contract liabilities, and $2.4 million of long-term contingent consideration. It also had $1.3 million in operating lease liabilities. The filing does not show a conventional bank-loan balance at year-end.
Changes, outlook and material issues
- Revenue recovery: Management attributed growth partly to a seasonally strong fourth quarter and continued recovery in dermatology visits after COVID-related disruption. PDT sales are typically stronger in the first and fourth quarters.
- Xepi supply: Manufacturing problems at its former supplier delayed supply and commercial expansion. Ferrer was qualifying a new North American manufacturer, with completion expected by early 2024; the timing and adequacy of future supply remain uncertain.
- Liquidity outlook: Management said available resources, including the investment it intended to sell and working-capital credit availability, were expected to fund operations for at least 12 months from the financial statements’ issuance. The company also warned it could need additional financing or reduce discretionary spending if plans or forecasts changed.
- Proposed credit facility: On March 9, 2023, the company received a commitment for a secured, asset-based revolving facility of up to $6.5 million, subject to borrowing-base limits, definitive documentation and other closing conditions. It was not a completed year-end facility.
- Maruho dispute: The company is pursuing ICC arbitration over alleged undisclosed manufacturing issues and whether it must repay the $7.3 million start-up financing. The repayment obligation and arbitration outcome remain material uncertainties.
- Settlement exposure: The company and Biofrontera AG remain jointly and severally liable for a $22.5 million settlement. At year-end, Biofrontera recorded a $6.2 million remaining settlement liability and a $6.4 million receivable from Biofrontera AG for its share. Failure by the related party to reimburse could leave Biofrontera liable for more than its agreed share.
- Other risks: The business depends on licensed products and third-party supply; Ameluz faces generic-entry and competition risks, while reimbursement, pricing, regulation and product acceptance affect sales. The company also disclosed potential dilution from outstanding warrants and equity awards.
- Nasdaq: After year-end, the company received notice that its share price did not meet Nasdaq’s $1 minimum bid requirement. It had until August 23, 2023, subject to applicable extensions, to regain compliance; a reverse stock split was among the options it said it might consider.
- Controls and audit: The independent auditor issued an unqualified opinion on the financial statements. Management reported that a previously identified material weakness relating to review of specialist work was remediated as of December 31, 2022. The auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Ameluz sales growth, product mix and the extent to which revenue remains concentrated in Ameluz.
- Progress and actual timing of Xepi’s replacement manufacturing qualification, and whether available inventory supports commercialization.
- Cash burn, the ability to liquidate the Biofrontera AG investment, and whether the proposed $6.5 million facility closed and is available under its borrowing-base terms.
- The status and financial consequences of the Maruho arbitration and repayment claims.
- Collection of the $6.4 million settlement reimbursement receivable and the company’s remaining settlement obligations.
- Nasdaq bid-price compliance, potential dilution from warrants and awards, and the effect of any further financing.